Description: Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Home Page: www.crossject.com
6 Rue Pauline Kergomard
Dijon,
21000
France
Phone:
33 3 80 54 98 50
Officers
| Name | Title |
|---|---|
| Mr. Patrick Alexandre | Co-Founder, CEO & Chairman of the Exec. Board |
| Dr. Isabelle Liebschütz | Chief Quality & Regulatory Officer and Member of Exec. Board |
| Mr. Henri de Parseval | COO of Engineering & Industry and Member of Exec. Board |
| Mr. Olivier Giré | COO of Specialty Pharma & Member of Exec. Board |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Supplies |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 37.1917 |
| Price-to-Sales TTM: | 18.4615 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 96 |